|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Betaxolol#Clinical Studies]] |
| {{Betaxolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Clinical Studies==
| |
| | |
| Optic nerve head damage and visual field loss are the result of a sustained elevated[[ intraocular pressure]] and poor ocular perfusion. BETOPTIC Ophthalmic Solution has the action of reducing elevated as well as normal[[ intraocular pressure]], and the mechanism of ocular hypotensive action appears to be a reduction of aqueous production as demonstrated by tonography and aqueous fluorophotometry. The onset of action with BETOPTIC Ophthalmic Solution can generally be noted within 30 minutes and the maximal effect can usually be detected 2 hours after topical administration. A single dose provides a 12-hour reduction in[[ intraocular pressure]]. Clinical observation of [[glaucoma]] patients treated with BETOPTIC Ophthalmic Solution for up to three years shows that the[[ intraocular pressure]] lowering effect is well maintained.
| |
| | |
| Clinical studies show that topical BETOPTIC Ophthalmic Solution reduces mean[[ intraocular pressure]] 25% from baseline. In trials using 22 mmHg as a generally accepted index of[[ intraocular pressure]] control, BETOPTIC Ophthalmic Solution was effective in more than 94% of the population studied, of which 73% were treated with the beta blocker alone. In controlled, double-masked studies, the magnitude and duration of the ocular hypotensive affect of BETOPTIC Ophthalmic Solution and ophthalmic timolol solution were clinically equivalent.
| |
| | |
| BETOPTIC Ophthalmic Solution has also been used successfully in [[glaucoma]] patients who have undergone a laser trabeculoplasty and have needed additional long-term ocular hypotensive therapy.
| |
| | |
| BETOPTIC Ophthalmic Solution has been well tolerated in [[glaucoma]] patients wearing hard or soft contact lenses and in aphakic patients.
| |
| | |
| BETOPTIC Ophthalmic Solution does not produce miosis or accommodative spasm which are frequently seen with miotic agents. The [[blurred vision]] and [[night blindness]] often associated with standard miotic therapy are not associated with BETOPTIC Ophthalmic Solution. Thus, patients with central [[lenticular opacities]] avoid the visual impairment caused by a constricted pupil.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BETOPTIC (BETAXOLOL HYDROCHLORIDE) SOLUTION/ DROPS [ALCON] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31b9b263-11fd-4495-83dd-ababf0d70e9e | publisher = | date = | accessdate = 3 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
|
| |
|
| [[Category:Beta blockers]] | | [[Category:Beta blockers]] |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |